APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA
The present disclosure relates to a new use of anlotinib, belongs to the technical field of drugs, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib may inhibit osteosarcoma and chondrosar...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ZHAN, Xiaole WANG, Zhuoying WANG, Gangyang CAI, Zhengdong SUN, Mengxiong TU, Lifan ZHANG, Tao WANG, Hongsheng HUA, Yingqi LI, Pu WANG, Xunqiang YANG, Zhaoqiang |
| description | The present disclosure relates to a new use of anlotinib, belongs to the technical field of drugs, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib may inhibit osteosarcoma and chondrosarcoma growth and metastasis. Anlotinib can significantly inhibit the growth of the osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest in said cell lines, and can also inhibit osteosarcoma cell line migration and invasion. It has also been discovered for the first time that anlotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3744325A4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3744325A4</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3744325A43</originalsourceid><addsrcrecordid>eNqNirEKwjAQQLM4iPoP9wF1sRHna5qSw3gXkiA4SCkSJ9FC_X_soLvTg_feUl0xBE8GMwmDdMByth7yJUoitnAkxmSB2FFDWWIFyF4yMTXVbEFStpIwGjnhnFowTriNP7VWi_vwmMrmy5WCzmbjtmV89WUah1t5lndvQ33Qut7tUdd_LB-ZUzJc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA</title><source>esp@cenet</source><creator>ZHAN, Xiaole ; WANG, Zhuoying ; WANG, Gangyang ; CAI, Zhengdong ; SUN, Mengxiong ; TU, Lifan ; ZHANG, Tao ; WANG, Hongsheng ; HUA, Yingqi ; LI, Pu ; WANG, Xunqiang ; YANG, Zhaoqiang</creator><creatorcontrib>ZHAN, Xiaole ; WANG, Zhuoying ; WANG, Gangyang ; CAI, Zhengdong ; SUN, Mengxiong ; TU, Lifan ; ZHANG, Tao ; WANG, Hongsheng ; HUA, Yingqi ; LI, Pu ; WANG, Xunqiang ; YANG, Zhaoqiang</creatorcontrib><description>The present disclosure relates to a new use of anlotinib, belongs to the technical field of drugs, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib may inhibit osteosarcoma and chondrosarcoma growth and metastasis. Anlotinib can significantly inhibit the growth of the osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest in said cell lines, and can also inhibit osteosarcoma cell line migration and invasion. It has also been discovered for the first time that anlotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells.</description><language>eng ; fre ; ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211020&DB=EPODOC&CC=EP&NR=3744325A4$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20211020&DB=EPODOC&CC=EP&NR=3744325A4$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHAN, Xiaole</creatorcontrib><creatorcontrib>WANG, Zhuoying</creatorcontrib><creatorcontrib>WANG, Gangyang</creatorcontrib><creatorcontrib>CAI, Zhengdong</creatorcontrib><creatorcontrib>SUN, Mengxiong</creatorcontrib><creatorcontrib>TU, Lifan</creatorcontrib><creatorcontrib>ZHANG, Tao</creatorcontrib><creatorcontrib>WANG, Hongsheng</creatorcontrib><creatorcontrib>HUA, Yingqi</creatorcontrib><creatorcontrib>LI, Pu</creatorcontrib><creatorcontrib>WANG, Xunqiang</creatorcontrib><creatorcontrib>YANG, Zhaoqiang</creatorcontrib><title>APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA</title><description>The present disclosure relates to a new use of anlotinib, belongs to the technical field of drugs, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib may inhibit osteosarcoma and chondrosarcoma growth and metastasis. Anlotinib can significantly inhibit the growth of the osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest in said cell lines, and can also inhibit osteosarcoma cell line migration and invasion. It has also been discovered for the first time that anlotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNirEKwjAQQLM4iPoP9wF1sRHna5qSw3gXkiA4SCkSJ9FC_X_soLvTg_feUl0xBE8GMwmDdMByth7yJUoitnAkxmSB2FFDWWIFyF4yMTXVbEFStpIwGjnhnFowTriNP7VWi_vwmMrmy5WCzmbjtmV89WUah1t5lndvQ33Qut7tUdd_LB-ZUzJc</recordid><startdate>20211020</startdate><enddate>20211020</enddate><creator>ZHAN, Xiaole</creator><creator>WANG, Zhuoying</creator><creator>WANG, Gangyang</creator><creator>CAI, Zhengdong</creator><creator>SUN, Mengxiong</creator><creator>TU, Lifan</creator><creator>ZHANG, Tao</creator><creator>WANG, Hongsheng</creator><creator>HUA, Yingqi</creator><creator>LI, Pu</creator><creator>WANG, Xunqiang</creator><creator>YANG, Zhaoqiang</creator><scope>EVB</scope></search><sort><creationdate>20211020</creationdate><title>APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA</title><author>ZHAN, Xiaole ; WANG, Zhuoying ; WANG, Gangyang ; CAI, Zhengdong ; SUN, Mengxiong ; TU, Lifan ; ZHANG, Tao ; WANG, Hongsheng ; HUA, Yingqi ; LI, Pu ; WANG, Xunqiang ; YANG, Zhaoqiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3744325A43</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2021</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHAN, Xiaole</creatorcontrib><creatorcontrib>WANG, Zhuoying</creatorcontrib><creatorcontrib>WANG, Gangyang</creatorcontrib><creatorcontrib>CAI, Zhengdong</creatorcontrib><creatorcontrib>SUN, Mengxiong</creatorcontrib><creatorcontrib>TU, Lifan</creatorcontrib><creatorcontrib>ZHANG, Tao</creatorcontrib><creatorcontrib>WANG, Hongsheng</creatorcontrib><creatorcontrib>HUA, Yingqi</creatorcontrib><creatorcontrib>LI, Pu</creatorcontrib><creatorcontrib>WANG, Xunqiang</creatorcontrib><creatorcontrib>YANG, Zhaoqiang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHAN, Xiaole</au><au>WANG, Zhuoying</au><au>WANG, Gangyang</au><au>CAI, Zhengdong</au><au>SUN, Mengxiong</au><au>TU, Lifan</au><au>ZHANG, Tao</au><au>WANG, Hongsheng</au><au>HUA, Yingqi</au><au>LI, Pu</au><au>WANG, Xunqiang</au><au>YANG, Zhaoqiang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA</title><date>2021-10-20</date><risdate>2021</risdate><abstract>The present disclosure relates to a new use of anlotinib, belongs to the technical field of drugs, and relates in particular to anlotinib inhibiting osteosarcoma and chondrosarcoma growth and metastasis. It has been discovered for the first time that anlotinib may inhibit osteosarcoma and chondrosarcoma growth and metastasis. Anlotinib can significantly inhibit the growth of the osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, induce cycle arrest in said cell lines, and can also inhibit osteosarcoma cell line migration and invasion. It has also been discovered for the first time that anlotinib can enhance the killing effect of the chemotherapeutic drug cisplatin on osteosarcoma cells.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP3744325A4 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA AND CHONDROSARCOMA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T15%3A55%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHAN,%20Xiaole&rft.date=2021-10-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3744325A4%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |